Biogen's fair value estimate has nudged higher to about $178.76 per share, even as its discount rate ticks up slightly to roughly 7.49 %, signaling a modestly higher perceived risk backdrop. The shift ...

If you have been wondering whether Biogen's recent share price makes it a bargain or a value trap, you are not alone. This article is designed to help you cut through the noise and focus on what the ...

Oct 30 (Reuters) - Biogen (BIIB.O), opens new tab beat Wall Street estimates for third-quarter profit, helped by better-than-expected sales of some of its multiple sclerosis treatments. The company, ...

The agreement complements Biogen's early-stage immunology pipeline by adding an oral mechanism with potential applicability across multiple immune-mediated diseases. C5aR1 plays a pivotal role in ...

The $70 million upfront deal adds to a portfolio of drugs Biogen has been growing in various immunological conditions since 2024. Biogen has licensed Vanqua Bio’s preclinical oral C5aR1 antagonist in ...

A California judge has ruled that Biogen owes Roche $124 million in royalties for its use of intellectual property developed more than 40 years ago by the Swiss company’s subsidiary Genentech that ...

Oct 1 (Reuters) - A California federal judge has determined that biotech company Biogen owes Roche's Genentech (ROG.S), opens new tab more than $88 million in patent royalties for sales of Biogen's ...

Biogen has discontinued all gene therapy programs using adeno-associated virus (AAV) capsids, instead shifting resources to modalities that have the highest likelihood of achieving better treatment ...

If Novo Nordisk A/S’s wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer’s disease, Biogen Inc.’s Chief Executive Officer Chris Viehbacher doesn’t see it as a ...

Biogen beat Q2 2025 revenue and EPS estimates, but core MS and SPINRAZA franchises continue to erode, offset only partially by new products. Launches like ZURZUVAE and LEQEMBI show promise, yet their ...

Biogen said it intends to invest an additional $2 billion over the next three years to expand operations at its largest manufacturing facilities within North Carolina’s Research Triangle Park (RTP).